Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.92 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.70 +9.1% TUNG 1.74 +3.0% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.92 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.70 +9.1% TUNG 1.74 +3.0% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0%
Other Routine +

Psyched Wellness Highlights U.S. Federal Policy Momentum Supporting Psychedelic Sector

Policy Tailwinds Mask Lingering FDA Safety Overhangs in Psyched Wellness

By The Northwire Desk — AI Analysis Apr 23, 2026 · 07:31 PSYC · 0.015 Psyched Wellness Ltd.
Executive Summary
  • The most recent release (April 23, 2026) highlights U.S. federal policy momentum supporting the psychedelic sector via a new executive order aimed at accelerating research and regulatory review for medical use.
  • The company anticipates these shifts will drive scientific advancement, increase investor capital, and expand commercial pathways for its Amanita muscaria-derived products.
  • Historical context shows a progression from operational milestones (January 2026 product sell-out) to financing (March 2026 private placement) to sector sentiment (April 2026 policy update).
  • Previous October 2025 news rated "Material - Negative" noted the FDA did not affirm safety for AME-1 in a New Dietary Ingredient Notification, though the company maintains compliance under FFDCA.
  • The April 23 release is an industry-wide sentiment piece rather than a specific company regulatory approval or revenue milestone.
Material Impact
  • Sentiment vs. Substance: While positive for the sector, the executive order does not resolve the specific FDA safety concerns regarding AME-1 raised in October 2025. The news lacks specific company-level catalysts such as new clinical trial data or regulatory clearance.
  • Market Reaction: The stock price has remained stagnant at $0.01 throughout March and April 2026, indicating the market does not view this policy news as a material valuation driver in isolation.
  • Financing Context: The recent March financing was dilutive (shares issued at $0.0101) and involved related party transactions with Gotham Green Fund III gaining board control. This suggests management is prioritizing capital preservation over organic growth, which tempers the optimism of the policy news.
  • Risk Profile: The "Routine - Positive" rating reflects that while the environment is improving, the company's fundamental risks (regulatory uncertainty, dilution) remain unchanged by this specific announcement.
PSYC · Price
Company Overview
  • Company: Psyched Wellness Ltd., focused on mushroom-derived consumer products using Amanita muscaria extract (AME-1).
  • Flagship Products: "Calmer" (double-strength AME-1 extract for relaxation) and "Santa" dietary supplement shot.
  • Development Status: Initial production runs completed; Calmer sold out first run in January 2026. Patent application filed for scaled-up extraction process (Aug 2025).
  • Regulatory Standing: Filed NDIN with FDA in July 2025; received negative safety concurrence but claims compliance under FFDCA.
Read the original news release →

More from Psyched Wellness Ltd.

Jun 10, 2026 · 17:16

Cash-burning micro‑cap supplement company faces leadership vacuum after CEO exit, with no safe‑harbor in sight.

Management Mar 20, 2026 · 09:17

Psyched Wellness Announces Closing of Private Placement and Shares for Debt Transaction and Resignation of a Director

Financings Mar 11, 2026 · 08:55

Psyched Wellness Announces Private Placement for Proceeds of up to C$1,719,306.94

Financings Jan 15, 2026 · 12:43

Psyched Wellness Sells Out of First Run of Calmer and Announces New Production Run

Other Oct 29, 2025 · 18:33

SEDAR Interim Financial Statements

None Oct 09, 2025 · 17:08

Psyched downplays FDA's safety comments on AME-1

Production / Operations